List of Innate Pharma patents

Patents where

Current Assignee

Name

Innate Pharma

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9388246 TLR3 binding agents	Patent 9388246 was granted and assigned to Innate Pharma on July, 2016 by the United States Patent and Trademark Office.		Innate Pharma	United States Patent and Trademark Office	9388246	July 12, 2016
‌ US Patent 10577416 Mica binding agents	Patent 10577416 was granted and assigned to Innate Pharma on March, 2020 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10577416	March 3, 2020
‌ US Patent 10329348 Treatment of cancers using anti-NKG2A agents	Patent 10329348 was granted and assigned to Innate Pharma on June, 2019 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10329348	June 25, 2019
‌ US Patent 10113003 Multispecific NK engager proteins	Patent 10113003 was granted and assigned to Innate Pharma on October, 2018 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10113003	October 30, 2018
‌ US Patent 11447545 Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer		Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11447545	September 20, 2022
‌ US Patent 10071169 Enzymatic conjugation of polypeptides	Patent 10071169 was granted and assigned to Innate Pharma on September, 2018 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10071169	September 11, 2018
‌ US Patent 11623954 Siglec-9-neutralizing antibodies	Patent 11623954 was granted and assigned to Innate Pharma on April, 2023 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11623954	April 11, 2023
‌ US Patent 10577419 KIR3DL2 binding agents	Patent 10577419 was granted and assigned to Innate Pharma on March, 2020 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10577419	March 3, 2020
‌ US Patent 10736963 Methods for detecting tissue infiltrating NK cells		Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10736963	August 11, 2020
‌ US Patent 10519234 NKp46 binding proteins	Patent 10519234 was granted and assigned to Innate Pharma on December, 2019 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10519234	December 31, 2019
‌ US Patent 11001629 Variable regions for NKp46 binding proteins	Patent 11001629 was granted and assigned to Innate Pharma on May, 2021 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11001629	May 11, 2021
‌ US Patent 9828427 Anti-KIR3D antibodies	Patent 9828427 was granted and assigned to Innate Pharma on November, 2017 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	9828427	November 28, 2017
‌ US Patent 11267897 Multispecific NK engager protein	Patent 11267897 was granted and assigned to Innate Pharma on March, 2022 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11267897	March 8, 2022
‌ US Patent 10174112 Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma	Patent 10174112 was granted and assigned to Innate Pharma on January, 2019 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10174112	January 8, 2019
‌ US Patent 10246510 KIR3DL2 binding agents	Patent 10246510 was granted and assigned to Innate Pharma on April, 2019 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10246510	April 2, 2019
‌ US Patent 10344087 Treatment of peripheral T cell lymphoma	Patent 10344087 was granted and assigned to Innate Pharma on July, 2019 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10344087	July 9, 2019
‌ US Patent 8735624 Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same	Patent 8735624 was granted and assigned to Innate Pharma on May, 2014 by the United States Patent and Trademark Office.		Innate Pharma	United States Patent and Trademark Office	8735624	May 27, 2014
‌ US Patent 11083785 Siglec-10 antibodies	Patent 11083785 was granted and assigned to Innate Pharma on August, 2021 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11083785	August 10, 2021
‌ US Patent 11066470 Humanized antibodies with increased stability	Patent 11066470 was granted and assigned to Innate Pharma on July, 2021 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11066470	July 20, 2021
‌ US Patent 11208480 Multispecific antigen binding proteins	Patent 11208480 was granted and assigned to Innate Pharma on December, 2021 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11208480	December 28, 2021
‌ US Patent 8017596 Phosphonates useful as modulators of T-γ-9-δ-2 activity	Patent 8017596 was granted and assigned to Innate Pharma on September, 2011 by the United States Patent and Trademark Office.		Innate Pharma	United States Patent and Trademark Office	8017596	September 13, 2011
‌ US Patent 11225519 Treatment of cancers using anti-NKG2A agents	Patent 11225519 was granted and assigned to Innate Pharma on January, 2022 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	11225519	January 18, 2022
‌ US Patent 10711063 Neutralization of inhibitory pathways in lymphocytes		Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10711063	July 14, 2020
‌ US Patent 10611824 Solid phase TGase-mediated conjugation of antibodies		Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10611824	April 7, 2020
‌ US Patent 10870700 Neutralization of inhibitory pathways in lymphocytes	Patent 10870700 was granted and assigned to Innate Pharma on December, 2020 by the United States Patent and Trademark Office.	Innate Pharma	Innate Pharma	United States Patent and Trademark Office	10870700	December 22, 2020

Results per page:

34 results

0 selected

34 results

0 selected